Display options
Cite
Sohn BS, Yuh YJ, Song HS, et al. Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncol Lett. 2015;10(2):1204-1210doi: 10.3892/ol.2015.3347.
Sohn, B. S., Yuh, Y. J., Song, H. S., Kim, B. S., Lee, K. H., Jang, J. S., & Kim, S. R. (2015). Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncology letters, 10(2), 1204-1210. https://doi.org/10.3892/ol.2015.3347
Sohn, Byeong Seok, et al. "Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer." Oncology letters vol. 10,2 (2015): 1204-1210. doi: https://doi.org/10.3892/ol.2015.3347
Sohn BS, Yuh YJ, Song HS, Kim BS, Lee KH, Jang JS, Kim SR. Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncol Lett. 2015 Aug;10(2):1204-1210. doi: 10.3892/ol.2015.3347. Epub 2015 Jun 10. PMID: 26622653; PMCID: PMC4509103.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2015 Aug;10(2):1204-1210. doi: 10.3892/ol.2015.3347. Epub 2015 Jun 10.

Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer.

Oncology letters

Byeong Seok Sohn, Young Jin Yuh, Hong Suk Song, Bong-Seog Kim, Kyung Hee Lee, Joung-Soon Jang, Sung Rok Kim

Affiliations

  1. Department of Internal Medicine, College of Medicine, Inje University Sanggye Paik Hospital, Seoul 139-707, Republic of Korea.
  2. Department of Hematooncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu 700-712, Republic of Korea.
  3. Department of Internal Medicine, Veterans Health Service Medical Center, Seoul 139-707, Republic of Korea.
  4. Division of Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu 702-701, Republic of Korea.
  5. Division of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul 139-707, Republic of Korea.

PMID: 26622653 PMCID: PMC4509103 DOI: 10.3892/ol.2015.3347

Abstract

In advanced or relapsed pancreatic cancer, mono- or duo-therapy has shown modest efficacy at best. The present study evaluated the efficacy of a triplet combination in relapsed or advanced pancreatic cancer. A total of 37 patients with adenocarcinoma of the pancreas in stage III/IV or with relapsed disease were treated with a gemcitabine, 5-fluorouracil and cisplatin (GFP) regimen every 3 weeks. Only 29 out of 37 patients were evaluable for response due to early treatment interruption in 8 patients. The overall response rate was 24.1% and the disease control rate was 68.9%. The progression-free survival (PFS) rate was 61.5, 30.9 and 17.6% at 3, 6 and 9 months, respectively, and the overall survival (OS) rate was 46.5 and 30.6% at 6 and 12 months, respectively. Grade 3/4 leukopenia, neutropenia and thrombocytopenia occurred in 18.4, 29.9 and 24.5% of 147 cycles, respectively. Old age and a poor performance status (PS) were associated with the early discontinuation of chemotherapy (P=0.038 and P=0.036, respectively). In patients <65 years old and with a PS of <2, the median PFS and OS times were 5.3 months and 10.3 months, respectively. Overall, although GFP resulted in acceptable response and survival rates, it does not appear to have marked superiority to gemcitabine-based single or duplet chemotherapy.

Keywords: 5-fluorouracil; cisplatin; gemcitabine; overall survival; pancreatic cancer; response

References

  1. Cancer. 2001 Aug 1;92(3):569-77 - PubMed
  2. J Clin Oncol. 2002 Aug 1;20(15):3270-5 - PubMed
  3. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73 - PubMed
  4. Ann Oncol. 2000 Oct;11(10):1267-72 - PubMed
  5. Biometrics. 1982 Mar;38(1):143-51 - PubMed
  6. J Clin Oncol. 2010 Apr 1;28(10):1645-51 - PubMed
  7. N Engl J Med. 2011 May 12;364(19):1817-25 - PubMed
  8. J Clin Oncol. 2003 Aug 1;21(15):2920-5 - PubMed
  9. Oncol Rep. 2010 May;23(5):1183-92 - PubMed
  10. Cancer. 2002 Feb 15;94(4):902-10 - PubMed
  11. J Clin Oncol. 2006 Aug 20;24(24):3946-52 - PubMed
  12. Semin Oncol. 1996 Oct;23(5 Suppl 10):16-24 - PubMed
  13. BMC Cancer. 2008 Mar 28;8:82 - PubMed
  14. Am J Clin Oncol. 1982 Dec;5(6):649-55 - PubMed
  15. Oncology. 2004;66(4):303-9 - PubMed
  16. Ann Oncol. 2000 Nov;11(11):1399-403 - PubMed
  17. Ann Oncol. 2004 Mar;15(3):474-7 - PubMed
  18. Br J Cancer. 2005 Jul 25;93(2):185-9 - PubMed
  19. Eur J Cancer. 1993;29A(2):203-4 - PubMed
  20. Oncology. 2001;60(1):8-18 - PubMed
  21. Clin Cancer Res. 1996 Mar;2(3):521-30 - PubMed
  22. J Chemother. 2008 Feb;20(1):119-25 - PubMed
  23. Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 - PubMed
  24. J Clin Oncol. 1999 Feb;17(2):585-92 - PubMed
  25. J Clin Oncol. 2007 Jun 1;25(16):2212-7 - PubMed
  26. Cancer. 1981 Jan 1;47(1):207-14 - PubMed
  27. J Clin Oncol. 2002 Mar 1;20(5):1182-91 - PubMed
  28. Cancer Invest. 2004;22(5):688-96 - PubMed
  29. J Clin Oncol. 2002 Mar 15;20(6):1512-8 - PubMed
  30. Ann Oncol. 2001 Jan;12(1):101-3 - PubMed
  31. J Clin Oncol. 1997 Jun;15(6):2403-13 - PubMed
  32. Am J Clin Oncol. 2001 Jun;24(3):296-8 - PubMed
  33. Br J Cancer. 1996 Jan;73(1):101-5 - PubMed

Publication Types